ECSP11010977A - Metilenaminas de tieno[2,3-d] pirimidina y su uso como antagonistas - Google Patents

Metilenaminas de tieno[2,3-d] pirimidina y su uso como antagonistas

Info

Publication number
ECSP11010977A
ECSP11010977A EC2011010977A ECSP11010977A ECSP11010977A EC SP11010977 A ECSP11010977 A EC SP11010977A EC 2011010977 A EC2011010977 A EC 2011010977A EC SP11010977 A ECSP11010977 A EC SP11010977A EC SP11010977 A ECSP11010977 A EC SP11010977A
Authority
EC
Ecuador
Prior art keywords
pyrimidine
methylenamins
tieno
antagonists
disorders
Prior art date
Application number
EC2011010977A
Other languages
English (en)
Inventor
Devraj Chakravarty
J Kent Barbay
Brian Christopher Shook
Aihua Wang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP11010977A publication Critical patent/ECSP11010977A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta invención se refiere a un nuevo tieno[2,3-d]pirimidina, A, y sus usos terapéuticos y profilácticos, en donde R1 y R2 se definieron en la descripción. Los trastornos que se tratan y/o previenen incluyen la enfermedad de Parkinson.
EC2011010977A 2008-10-13 2011-04-13 Metilenaminas de tieno[2,3-d] pirimidina y su uso como antagonistas ECSP11010977A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10478108P 2008-10-13 2008-10-13
US12/479,158 US20100093702A1 (en) 2008-10-13 2009-06-05 METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS

Publications (1)

Publication Number Publication Date
ECSP11010977A true ECSP11010977A (es) 2011-05-31

Family

ID=42099433

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011010977A ECSP11010977A (es) 2008-10-13 2011-04-13 Metilenaminas de tieno[2,3-d] pirimidina y su uso como antagonistas

Country Status (17)

Country Link
US (1) US20100093702A1 (es)
EP (1) EP2350092A1 (es)
JP (1) JP2012505264A (es)
KR (1) KR20110071109A (es)
CN (1) CN102245614A (es)
AU (1) AU2009303694A1 (es)
BR (1) BRPI0920217A2 (es)
CA (1) CA2740406A1 (es)
CL (1) CL2011000832A1 (es)
CO (1) CO6321169A2 (es)
EA (1) EA201170563A1 (es)
EC (1) ECSP11010977A (es)
IL (1) IL212173A0 (es)
MX (1) MX2011003962A (es)
PE (1) PE20110423A1 (es)
WO (1) WO2010045006A1 (es)
ZA (1) ZA201103489B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011022191A1 (en) 2009-08-21 2011-02-24 The Trustees Of The University Of Pennsylvania Adamantane analogs
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
US9884832B2 (en) * 2011-12-06 2018-02-06 The Trustees Of The University Of Pennsylvania Inhibitors targeting drug-resistant influenza A
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2018137036A1 (en) 2017-01-26 2018-08-02 The Royal Institution For The Advancement Of Learning / Mcgill University Substituted bicyclic pyrimidine-based compounds and compositions and uses thereof
EA201992780A1 (ru) 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
TW202500130A (zh) * 2023-05-09 2025-01-01 美商安進公司 用作１５－前列腺素脫氫酶調節劑之５，６－稠合和６，６－稠合的雙環醇和醚及組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1099150C (zh) * 1996-02-16 2003-01-15 阿苏拉布股份有限公司 包含利用光生伏打电池为蓄电池充电的充电装置的钟表
US5939432A (en) * 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
DE60110219T2 (de) * 2000-05-26 2006-03-09 Schering Corp. Adenosin a2a rezeptor antagonisten
GB0100620D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.

Also Published As

Publication number Publication date
KR20110071109A (ko) 2011-06-28
JP2012505264A (ja) 2012-03-01
MX2011003962A (es) 2011-05-03
AU2009303694A1 (en) 2010-04-22
US20100093702A1 (en) 2010-04-15
BRPI0920217A2 (pt) 2015-12-22
CN102245614A (zh) 2011-11-16
IL212173A0 (en) 2011-06-30
CO6321169A2 (es) 2011-09-20
ZA201103489B (en) 2012-11-28
CA2740406A1 (en) 2010-04-22
CL2011000832A1 (es) 2011-07-15
EA201170563A1 (ru) 2011-10-31
EP2350092A1 (en) 2011-08-03
WO2010045006A1 (en) 2010-04-22
PE20110423A1 (es) 2011-07-08

Similar Documents

Publication Publication Date Title
ECSP11010977A (es) Metilenaminas de tieno[2,3-d] pirimidina y su uso como antagonistas
EP2248816A4 (en) 2-ALKYLAMINO-3-ARYLSULFONYLCYCLOALCAN [E OR D] PYRAZOLO [1,5-A] PYRIMIDINE / ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
CL2008001709A1 (es) Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
ECSP11011534A (es) 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octano- o heptano-nitrilo como inhibidores de jak
CR10149A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico
CL2008001374A1 (es) Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia.
CL2012003293A1 (es) Compuestos derivados de aminopirimidina, como moduladores de la proteina quinasa rica en repeticiones leucina 2 (lrrk2); composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de parkinson.
HN2008001530A (es) Compuestos de amino pirimidina 2,6- sustituidos -4-monosustituidos como antagonistas del receptor de prostaglandina d2
MX388468B (es) Compuestos multicíclicos y métodos de uso de los mismos.
MX2009010728A (es) Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora.
ME01532B (me) Jedinjenja
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
MX394094B (es) PYRAZOLO [1, 5-a] PIRIMIDINAS SUSTITUIDAS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MÉDICOS.
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
CL2011001972A1 (es) Compuestos derivados de pirimidina fusionada, inhibidores akt; proceso de preparacion de dichos compuestos y compuestos intermediarios; compuestos intermediarios; composicion farmaceutica que los comprende; combinacion farmaceutica que los comprende y sus usos en el tratamiento de enfermedades hiperproliferativas.
ZA201000314B (en) 2, 3-dihydrobenzo[1, 4] dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous system diseases
CR20110100A (es) Nuevos derivados de sulfamida sustituida
DE602007004999D1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen-derivate als orexinrezeptor-antagonisten
BRPI0614397A2 (pt) compostos de pirimidina como moduladores de receptor de serotonina
SV2005002061A (es) Derivados de piridilo y su uso como antagonistas del receptor mglu5 ref. x-16538
ECSP12011923A (es) Nuevas formas polimorfas de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo
UY31420A1 (es) Arilindenopirimidinas y su uso como antagonistas del receptor a2a de adenosina
CO6290689A2 (es) Derivados de 1,2,3,4-tetrahidropirrolo[1,2]pirazina-6-carboxamidas y de 2,3,4,5-tetrahidropirrol[1,2][1,4]-diazepina -7-carboxamidas su preparacion y su aplicacion en terapeutica
AR069026A1 (es) Arilindenopirimidinas y su uso como antagonistas de los receptores de adenosina a₂a
ECSP12011842A (es) ARILINDENOPIRIMIDINAS SUSTITUIDAS CON ALQUILO Y SU USO COMO ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a ALTAMENTE SELECTIVOS